B+
Bull case
25%
Probability
Target price
$8.50
+24.5% vs current
EDSA
Edesa BiotechCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$5.00
-26.8% vs current
B-
Bear case
30%
Probability
Target price
$2.00
-70.7% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+21.1
Score
AI commentary
Primary-source evidence remains constructive on paridiprubart, but the deterministic prior is still mildly negative and catalyst density is low. Coverage is limited, recent external confirmation is sparse, and forward visibility is thinner than a standard report, so sentiment still reads as a cautious monitoring setup rather than a clean bullish re-rate.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-06-30eventEB06 vitiligo study start is a tangible 2026 checkpointHigh impact
Management said Health Canada has cleared a Phase 2 proof-of-concept study for EB06 in moderate-to-severe nonsegmental vitiligo, that FDA discussions are ongoing, and that enrollment is anticipated by midyear 2026 subject to regulatory approval; hitting that timeline would show pipeline progress beyond paridiprubart [#10-Q-2026-02-13].
2026-09-30catalystRunway and financing overhang remains the clearest near-term swing factorHigh impact
The December 31, 2025 10-Q disclosed $12.1 million of cash, roughly $2.1 million of quarterly operating cash outflow, an active ATM facility, and explicit going-concern uncertainty tied to the need for additional funding; that keeps dilution or other financing activity as the most immediate stock-moving variable [#10-Q-2026-02-13].
2027-03-31catalystParidiprubart follow-through is still the main upside driver but remains execution-heavyHigh impact
The February 24, 2026 8-K reported statistically significant mortality reduction in a 278-patient Phase 3 ARDS population, while the 10-Q described ongoing U.S. government-funded study work and Canadian SRF support of up to C$23 million for study completion, approvals, and manufacturing scale-up; that combination preserves a path to regulatory and development progress, but timing is still uncertain [#8-K-2026-02-24] [#10-Q-2026-02-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology